NicoleRaleigh said:VanRx_Mike said: ...cardiovascular risk is just another fad...
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:
Weight: consistent downtrend, -2.3 lbs/week average
Fasting glucose (finger stick): stable at 86 mg/dL
Blood pressure (home): 118/72 average
Resting heart rate: 66 bpm (down from 82)
Waist circumference: down 16 inches total
The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.
NicoleRaleigh said:VanRx_Mike said: ...cardiovascular risk is just another fad...
I want to bring up the cardiovascular angle on cardiovascular risk.
The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.
For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
PeptideMeter — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsNicoleRaleigh said:VanRx_Mike said: ...cardiovascular risk is just another fad...
Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.
SteveThurs said:I want to bring up the cardiovascular angle on cardiovascular risk.
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:
- NT-proBNP: 55 pg/mL (normal, cardiac function preserved)
- Lp(a): 35 nmol/L (genetic, unchanged — expected)
- ApoB: dropped from 140 to 95 mg/dL (excellent response)
- Coronary calcium score: 0 (unchanged from baseline — reassuring)
The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.